Press Room


    Press Release - June 19, 2006

    Dr. David White to Become Principal Researcher and Chair of Scientific Advisory Board

    Kelowna, B.C. -- Pheromone Sciences Corp. ("Pheromone") is pleased to announce that Dr. David White of the University of Western Ontario has agreed to become the principal researcher for the Company's diabetes research project and has accepted an appointment as Chair of the Company's Scientific Advisory board ("SAB"). Pheromone recently completed a $3.2 million private placement to fund this project, and it will be the Company's primary research focus.

    As SAB Chair, Dr. White's first responsibility is to recruit members to the SAB who have significant standing in the community of diabetic and xenotransplantation researchers. "The scientists on the SAB shortlist are some of the finest minds in the field and they have an intricate understanding of the science of this project, " states Dr. White. "I believe their contributions will be invaluable in ensuring the best design and execution of this diabetes product development project"." The SAB will provide oversight of the Company's research efforts and provide scientific input and interpretation of the project's methodology, progression and results.

    About Dr. White

    Dr White graduated from the Universities of Surrey and Cambridge and in 1975 was awarded a PhD in Immunology from Cambridge. He was Board Certified in Pathology in 1984 (MRCPath) and elected as a fellow of the college in 1995 (FRCPath). Dr White holds appointments on the Editorial Board of several major international transplantation journals, has served as a member of government advisory committees, and has been awarded a number of academic prizes for his work. He has published over 300 scientific papers on subjects related to transplant immunology.

    Dr. White first became interested in transplantation while undertaking research at the Department of Surgery at Cambridge University in the 1970s. In conjunction with Professor Sir Roy Calne, he undertook much of the original experimental and clinical work that led to the development of the immunosuppressive drug Cyclosporin A. The drug became pivotal in preventing organ rejection following transplantation and has allowed new transplantation procedures to be developed.

    His research into the immunological process underlying rejection of organ transplants led him to investigate how the immune system could be modified to enable successful transplantation of non-human organs - potentially solving the 'organ donor crisis'. These studies led Dr White in 1992 to create the world's first genetically engineered pigs

    whose organs and tissues were modified for transplantation into humans. In 1984 he and transplant surgeon John Wallwork founded Imutran Limited, which became a wholly owned subsidiary of Novartis Pharma AG in 1996., and Dr White was appointed to the Novartis Global Research Management Board. In 2000 Dr White was appointed the Novartis/Stiller Professor of Xenotransplantation at the University of Western Ontario.

    About the Research Project

    Pheromone's research project is intended to lead to an USFDA licensed procedure for treating diabetes by transplanting into humans a device containing pig islet and Sertoli cells. The islet cells produce insulin almost identical to that found in humans, and the Sertoli cells naturally protect the islet cells from attack by the body's immune system. The research is based on several proof of concept experiments completed by Dr. White and others.

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing medical technologies.

    ON BEHALF OF THE BOARD "Dev Randhawa" Dev Randhawa, President

    For further information contact:

    Mr. Phil Morehouse Pheromone Sciences Corp. TEL: (250) 868-8177 FAX: (250) 868-8493

    Mr. Justin Leushner Sertonex Inc. TEL: (519) 639-7867 FAX: (519) 858-5142


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News